HOW DID A PERCUTANEOUS CORONARY INTERVENTION/CORONARY ARTERY BYPASS GRAFTING RANDOMISED TRIAL GENERATE THE ANATOMIC SYNTAX SCORE? Following the CABRI1 and ARTS2 trials on multivessel disease, a challenging new trial was proposed to surgeons, namely the SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) trial, sponsored by Boston Scientific as an IDE FDA trial on the use of the TAXUS™ stent (Boston Scientific, Marlborough, MA, USA) in three-vessel disease and left main. Actually, the left main component of the trial was a proposal made by Marie-Claude Morice and Antonio Colombo. A surgeon, Friedrich Mohr (...
Patrick W. Serruys, Ply Chichareon, Rodrigo Modolo, David M. Leaman, Johan H. C. Reiber, Håkan Emanuelsson, Carlo Di Mario, Nico H.J. Pijls, Marie-Angèle Morel, Marco Valgimigli, Vasim Farooq, David van Klaveren, Davide Capodanno, Daniele Andreini, Christos V. Bourantas, Justin E. Davies, Adrian Banning, Javier Escaned, Jan J. Piek, Mauro Echavarría‐Pinto, Charles A. Taylor, Brian Thomsen, Carlos Collet, Giulio Pompilio, Antonio L. Bartorelli, Ben Glocker, Ovidiu Dressler, Gregg W. Stone, Yoshinobu Onuma
Mouin Abdallah, Kaijun Wang, Elizabeth A. Magnuson, Ruben L.J. Osnabrugge, A. Pieter Kappetein, Marie‐Claude Morice, Friedrich Mohr, Patrick W. Serruys, David J. Cohen
Discussion(0)
No comments yet. Be the first to comment.